In summary, our pan-cancer analysis revealed that CHD5 was abnormally expressed in cancer samples across different types of cancers, and the abnormal expression of CHD5 correlated with the clinicopathological features and patient prognosis, especially in tumors related to the nervous system. This evidence concerns the gene CHD5 and cancer.